文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

Hmga2与JAK2V617F协同促进骨髓增殖性肿瘤发生发展

Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms.
PubMed 文献 · Blood Adv · 2017-06-14

本研究通过构建3'非翻译区缺失导致Hmga2过表达的ΔHmga2/JAK2V617F小鼠,发现其较JAK2V617F小鼠表现出更严重的白细胞增多、贫血和脾肿大及生存期缩短,而骨髓纤维化严重程度相当;Hmga2在造血干细胞水平促进骨髓增殖性肿瘤进展,并可能通过上调EZH2靶基因发挥作用。

要点

  • ΔHmga2/JAK2V617F小鼠较JAK2V617F小鼠白细胞增多、贫血、脾肿大更重且生存期缩短,骨髓纤维化程度相当。
  • ΔHmga2/JAK2V617F细胞在连续骨髓移植中重现更严重的骨髓增殖性肿瘤,提示Hmga2在造血干细胞水平促进进展。
  • Hmga2增强JAK2V617F红系祖细胞凋亡可能加重贫血;敲除Hmga2可改善JAK2V617F/Ezh2Δ/wild-type小鼠的贫血和脾肿大。

核心结论

  • Hmga2在骨髓增殖性肿瘤进展中起关键作用,与JAK2V617F协同导致更严重的疾病表型。

研究设计与样本

  • 研究构建了3'非翻译区缺失导致Hmga2过表达的ΔHmga2/JAK2V617F小鼠模型,并与JAK2V617F小鼠进行比较。
  • 研究还进行了连续骨髓移植实验以及JAK2V617F/Ezh2Δ/wild-type小鼠中Hmga2敲除的实验。
  • 研究分析了骨髓增殖性肿瘤患者中HMGA2 mRNA水平与MIRlet-7抑制及PRC2突变的相关性。

主要发现

  • 与JAK2V617F小鼠相比,ΔHmga2/JAK2V617F小鼠表现出更严重的白细胞增多、贫血和脾肿大,以及缩短的生存期,而骨髓纤维化严重程度相当。
  • 在连续骨髓移植中,ΔHmga2/JAK2V617F细胞较JAK2V617F细胞表现出更强的重建造血能力,并重现严重骨髓增殖性肿瘤。
  • Hmga2增强JAK2V617F红系祖细胞的凋亡,可能加重贫血。
  • 在ΔHmga2/JAK2V617F造血干/祖细胞中上调的基因中,超过30%与JAK2V617F/Ezh2Δ/Δ造血干/祖细胞中Ezh2缺失去抑制的基因重叠。
  • 敲除Hmga2可改善JAK2V617F/Ezh2Δ/wild-type小鼠的贫血和脾肿大,且MIRlet-7抑制和PRC2突变与骨髓增殖性肿瘤患者(尤其是骨髓纤维化)中HMGA2 mRNA水平升高相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-mobility group AT-hook 2 (HMGA2) is crucial for the self-renewal of fetal hematopoietic stem cells (HSCs) but is downregulated in adult HSCs via repression by MIRlet-7 and the polycomb-recessive complex 2 (PRC2) including EZH2. The HMGA2 messenger RNA (mRNA) level is often elevated in patients with myelofibrosis that exhibits an advanced myeloproliferative neoplasm (MPN) subtype, and deletion of Ezh2 promotes the progression of severe myelofibrosis in JAK2V617F mice with upregulation of several oncogenes such as Hmga2. However, the direct role of HMGA2 in the pathogenesis of MPNs remains unknown. To clarify the impact of HMGA2 on MPNs carrying the driver mutation, we generated ΔHmga2/JAK2V617F mice overexpressing Hmga2 due to deletion of the 3' untranslated region. Compared with JAK2V617F mice, ΔHmga2/JAK2V617F mice exhibited more severe leukocytosis, anemia and splenomegaly, and shortened survival, whereas severity of myelofibrosis was comparable. ΔHmga2/JAK2V617F cells showed a greater repopulating ability that reproduced the severe MPN compared with JAK2V617F cells in serial bone marrow transplants, indicating that Hmga2 promotes MPN progression at the HSC level. Hmga2 also enhanced apoptosis of JAK2V617F erythroblasts that may worsen anemia. Relative to JAK2V617F hematopoietic stem and progenitor cells (HSPCs), over 30% of genes upregulated in ΔHmga2/JAK2V617F HSPCs overlapped with those derepressed by Ezh2 loss in JAK2V617F/Ezh2Δ/Δ HSPCs, suggesting that Hmga2 may facilitate upregulation of Ezh2 targets. Correspondingly, deletion of Hmga2 ameliorated anemia and splenomegaly in JAK2V617F/Ezh2Δ/wild-type mice, and MIRlet-7 suppression and PRC2 mutations correlated with the elevated HMGA2 mRNA levels in patients with MPNs, especially myelofibrosis. These findings suggest the crucial role of HMGA2 in MPN progression.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ueda K, Ikeda K, Ikezoe T, et al. Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Adv. 2017. PMID: 29296743. doi:10.1182/bloodadvances.2017004457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。